| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The influence of finasteride on the development of prostate cancer.
|
N Engl J Med
|
2003
|
24.45
|
|
2
|
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter.
|
N Engl J Med
|
2004
|
15.10
|
|
3
|
Lung cancer.
|
N Engl J Med
|
2008
|
13.49
|
|
4
|
Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.
|
JAMA
|
2006
|
11.22
|
|
5
|
Vitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
JAMA
|
2011
|
11.02
|
|
6
|
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial.
|
Lancet
|
2008
|
10.74
|
|
7
|
The BATTLE trial: personalizing therapy for lung cancer.
|
Cancer Discov
|
2011
|
7.57
|
|
8
|
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs.
|
Mayo Clin Proc
|
2015
|
4.70
|
|
9
|
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial.
|
J Natl Cancer Inst
|
2007
|
4.64
|
|
10
|
Statins and cancer prevention.
|
Nat Rev Cancer
|
2005
|
4.12
|
|
11
|
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
4.02
|
|
12
|
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer.
|
J Natl Cancer Inst
|
2006
|
3.62
|
|
13
|
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
|
J Clin Oncol
|
2009
|
3.51
|
|
14
|
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.
|
Clin Cancer Res
|
2012
|
3.48
|
|
15
|
Retracted
The influence of resection and aneuploidy on mortality in oral leukoplakia.
|
N Engl J Med
|
2004
|
3.22
|
|
16
|
Podoplanin: a novel marker for oral cancer risk in patients with oral premalignancy.
|
J Clin Oncol
|
2008
|
3.16
|
|
17
|
Randomized, double-blind, placebo-controlled phase IIb trial of the cyclooxygenase inhibitor ketorolac as an oral rinse in oropharyngeal leukoplakia.
|
Clin Cancer Res
|
2004
|
2.95
|
|
18
|
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome.
|
J Natl Cancer Inst
|
2012
|
2.79
|
|
19
|
Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.
|
Clin Cancer Res
|
2002
|
2.71
|
|
20
|
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
|
Cancer Discov
|
2012
|
2.68
|
|
21
|
Randomized phase III trial of low-dose isotretinoin for prevention of second primary tumors in stage I and II head and neck cancer patients.
|
J Natl Cancer Inst
|
2006
|
2.61
|
|
22
|
Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity.
|
J Clin Oncol
|
2005
|
2.48
|
|
23
|
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy.
|
Expert Opin Ther Targets
|
2012
|
2.42
|
|
24
|
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer.
|
J Natl Cancer Inst
|
2009
|
2.34
|
|
25
|
Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.
|
Clin Cancer Res
|
2006
|
2.24
|
|
26
|
Use of pharmacologic interventions for breast cancer risk reduction: American Society of Clinical Oncology clinical practice guideline.
|
J Clin Oncol
|
2013
|
2.21
|
|
27
|
Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention.
|
J Clin Oncol
|
2005
|
1.98
|
|
28
|
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection.
|
J Urol
|
2007
|
1.97
|
|
29
|
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial.
|
J Clin Oncol
|
2007
|
1.95
|
|
30
|
Meta-analysis of the impact of human papillomavirus (HPV) on cancer risk and overall survival in head and neck squamous cell carcinomas (HNSCC).
|
Head Neck Oncol
|
2010
|
1.94
|
|
31
|
The 15-lipoxygenase-1 product 13-S-hydroxyoctadecadienoic acid down-regulates PPAR-delta to induce apoptosis in colorectal cancer cells.
|
Proc Natl Acad Sci U S A
|
2003
|
1.84
|
|
32
|
Phase II study of dasatinib in patients with advanced non-small-cell lung cancer.
|
J Clin Oncol
|
2010
|
1.79
|
|
33
|
An attenuated adenovirus, ONYX-015, as mouthwash therapy for premalignant oral dysplasia.
|
J Clin Oncol
|
2003
|
1.78
|
|
34
|
Induction chemotherapy and cetuximab for locally advanced squamous cell carcinoma of the head and neck: results from a phase II prospective trial.
|
J Clin Oncol
|
2009
|
1.74
|
|
35
|
Mortality risk from squamous cell skin cancer.
|
J Clin Oncol
|
2005
|
1.74
|
|
36
|
Phase II study of induction chemotherapy with paclitaxel, ifosfamide, and carboplatin (TIC) for patients with locally advanced squamous cell carcinoma of the head and neck.
|
Cancer
|
2002
|
1.71
|
|
37
|
Phase III prevention trial of fenretinide in patients with resected non-muscle-invasive bladder cancer.
|
Clin Cancer Res
|
2008
|
1.68
|
|
38
|
Baseline selenium status and effects of selenium and vitamin e supplementation on prostate cancer risk.
|
J Natl Cancer Inst
|
2014
|
1.67
|
|
39
|
Science peels the onion of selenium effects on prostate carcinogenesis.
|
J Natl Cancer Inst
|
2004
|
1.66
|
|
40
|
Prospective risk-adjusted [18F]Fluorodeoxyglucose positron emission tomography and computed tomography assessment of radiation response in head and neck cancer.
|
J Clin Oncol
|
2009
|
1.66
|
|
41
|
Chronic inflammation in benign prostate tissue is associated with high-grade prostate cancer in the placebo arm of the prostate cancer prevention trial.
|
Cancer Epidemiol Biomarkers Prev
|
2014
|
1.61
|
|
42
|
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types.
|
Carcinogenesis
|
2005
|
1.61
|
|
43
|
Randomized trial of adjuvant 13-cis-retinoic acid and interferon alfa for patients with aggressive skin squamous cell carcinoma.
|
J Clin Oncol
|
2007
|
1.61
|
|
44
|
COX-2 inhibitors and other nonsteroidal anti-inflammatory drugs in genitourinary cancer.
|
Semin Oncol
|
2004
|
1.59
|
|
45
|
High-dose fenretinide in oral leukoplakia.
|
Cancer Prev Res (Phila)
|
2009
|
1.59
|
|
46
|
Prevention of prostate cancer with finasteride: US/European perspective.
|
Eur Urol
|
2003
|
1.59
|
|
47
|
Whole exome sequencing of adenoid cystic carcinoma.
|
J Clin Invest
|
2013
|
1.58
|
|
48
|
Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants.
|
Cancer Prev Res (Phila)
|
2009
|
1.57
|
|
49
|
Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: Incidence, variability, and clinicopathologic significance.
|
Clin Cancer Res
|
2010
|
1.55
|
|
50
|
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes.
|
J Clin Oncol
|
2005
|
1.54
|
|
51
|
Randomized, double-blind, placebo-controlled, phase III chemoprevention trial of selenium supplementation in patients with resected stage I non-small-cell lung cancer: ECOG 5597.
|
J Clin Oncol
|
2013
|
1.54
|
|
52
|
Adenoma recurrences after resection of colorectal carcinoma: results from the Southwest Oncology Group 9041 calcium chemoprevention pilot study.
|
Ann Surg Oncol
|
2003
|
1.53
|
|
53
|
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.
|
J Natl Cancer Inst
|
2007
|
1.52
|
|
54
|
Epithelial to mesenchymal transition in head and neck squamous carcinoma: association of Src activation with E-cadherin down-regulation, vimentin expression, and aggressive tumor features.
|
Cancer
|
2008
|
1.50
|
|
55
|
Phase II and biologic study of interferon alfa, retinoic acid, and cisplatin in advanced squamous skin cancer.
|
J Clin Oncol
|
2002
|
1.50
|
|
56
|
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited.
|
J Clin Oncol
|
2005
|
1.50
|
|
57
|
Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
|
J Clin Oncol
|
2008
|
1.49
|
|
58
|
Phase III trial of selenium to prevent prostate cancer in men with high-grade prostatic intraepithelial neoplasia: SWOG S9917.
|
Cancer Prev Res (Phila)
|
2011
|
1.38
|
|
59
|
Molecular targets for cancer chemoprevention.
|
Nat Rev Drug Discov
|
2009
|
1.38
|
|
60
|
Genetic variation in MicroRNA genes and risk of oral premalignant lesions.
|
Mol Carcinog
|
2010
|
1.32
|
|
61
|
CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma.
|
Cancer Res
|
2012
|
1.32
|
|
62
|
Algorithmic guided screening of drug combinations of arbitrary size for activity against cancer cells.
|
Mol Cancer Ther
|
2009
|
1.28
|
|
63
|
Genome-wide association study of survival in non-small cell lung cancer patients receiving platinum-based chemotherapy.
|
J Natl Cancer Inst
|
2011
|
1.27
|
|
64
|
Randomized trial of 13-cis retinoic acid compared with retinyl palmitate with or without beta-carotene in oral premalignancy.
|
J Clin Oncol
|
2008
|
1.25
|
|
65
|
Pilot randomized phase II study of celecoxib in oral premalignant lesions.
|
Clin Cancer Res
|
2008
|
1.23
|
|
66
|
The critical role of 15-lipoxygenase-1 in colorectal epithelial cell terminal differentiation and tumorigenesis.
|
Cancer Res
|
2005
|
1.22
|
|
67
|
Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer.
|
Clin Cancer Res
|
2003
|
1.22
|
|
68
|
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis.
|
Cancer
|
2008
|
1.21
|
|
69
|
Minority recruitment to the Selenium and Vitamin E Cancer Prevention Trial (SELECT).
|
Clin Trials
|
2005
|
1.21
|
|
70
|
The dilemma and promise of cancer chemoprevention.
|
Nat Clin Pract Oncol
|
2006
|
1.18
|
|
71
|
The role of prevention in oncology practice: results from a 2004 survey of American Society of Clinical Oncology members.
|
J Clin Oncol
|
2006
|
1.18
|
|
72
|
Cyclic AMP response element-binding protein overexpression: a feature associated with negative prognosis in never smokers with non-small cell lung cancer.
|
Cancer Res
|
2008
|
1.18
|
|
73
|
Transition of a clinical trial into translational research: the prostate cancer prevention trial experience.
|
Cancer Prev Res (Phila)
|
2010
|
1.17
|
|
74
|
Elevated epithelial insulin-like growth factor expression is a risk factor for lung cancer development.
|
Cancer Res
|
2009
|
1.15
|
|
75
|
Cyclin D1 gene polymorphism as a risk factor for oral premalignant lesions.
|
Carcinogenesis
|
2006
|
1.14
|
|
76
|
p53 mutations in human aggressive and nonaggressive basal and squamous cell carcinomas.
|
Clin Cancer Res
|
2003
|
1.13
|
|
77
|
Genetic variants in inflammation-related genes are associated with radiation-induced toxicity following treatment for non-small cell lung cancer.
|
PLoS One
|
2010
|
1.12
|
|
78
|
Profiling lipoxygenase metabolism in specific steps of colorectal tumorigenesis.
|
Cancer Prev Res (Phila)
|
2010
|
1.12
|
|
79
|
Prognostic impact of insulin receptor expression on survival of patients with nonsmall cell lung cancer.
|
Cancer
|
2011
|
1.12
|
|
80
|
Molecular signatures of lung cancer--toward personalized therapy.
|
N Engl J Med
|
2007
|
1.12
|
|
81
|
The transcription factor GATA-6 is overexpressed in vivo and contributes to silencing 15-LOX-1 in vitro in human colon cancer.
|
FASEB J
|
2006
|
1.11
|
|
82
|
Glycogen synthase kinase-3 beta is involved in the phosphorylation and suppression of androgen receptor activity.
|
J Biol Chem
|
2004
|
1.10
|
|
83
|
Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast.
|
Cancer Epidemiol Biomarkers Prev
|
2003
|
1.09
|
|
84
|
The histone deacetylase inhibitor suberoylanilide hydroxamic acid induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
|
Cancer Res
|
2004
|
1.08
|
|
85
|
Nucleotide excision repair pathway genes and oral premalignant lesions.
|
Clin Cancer Res
|
2007
|
1.08
|
|
86
|
Induction of cyclooxygenase-2 by benzo[a]pyrene diol epoxide through inhibition of retinoic acid receptor-beta 2 expression.
|
Oncogene
|
2005
|
1.07
|
|
87
|
Her-2/neu gene amplification in ductal carcinoma in situ of the breast.
|
Cancer Epidemiol Biomarkers Prev
|
2002
|
1.06
|
|
88
|
Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules.
|
Cancer Prev Res (Phila)
|
2010
|
1.06
|
|
89
|
Pathway-based serum microRNA profiling and survival in patients with advanced stage non-small cell lung cancer.
|
Cancer Res
|
2013
|
1.06
|
|
90
|
Hypermethylation of the retinoic acid receptor-beta(2) gene in head and neck carcinogenesis.
|
Clin Cancer Res
|
2004
|
1.05
|
|
91
|
GATA-6 transcriptional regulation of 15-lipoxygenase-1 during NSAID-induced apoptosis in colorectal cancer cells.
|
Cancer Res
|
2002
|
1.05
|
|
92
|
Novel chromosomal rearrangements and break points at the t(6;9) in salivary adenoid cystic carcinoma: association with MYB-NFIB chimeric fusion, MYB expression, and clinical outcome.
|
Clin Cancer Res
|
2011
|
1.05
|
|
93
|
Serum signature of hypoxia-regulated factors is associated with progression after induction therapy in head and neck squamous cell cancer.
|
Mol Cancer Ther
|
2010
|
1.03
|
|
94
|
Reduced DNA repair capacity for removing tobacco carcinogen-induced DNA adducts contributes to risk of head and neck cancer but not tumor characteristics.
|
Clin Cancer Res
|
2010
|
1.02
|
|
95
|
Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei.
|
J Biol Chem
|
2003
|
1.02
|
|
96
|
Phase IB randomized, double-blinded, placebo-controlled, dose escalation study of polyphenon E in women with hormone receptor-negative breast cancer.
|
Cancer Prev Res (Phila)
|
2012
|
1.01
|
|
97
|
Global evaluation of Eph receptors and ephrins in lung adenocarcinomas identifies EphA4 as an inhibitor of cell migration and invasion.
|
Mol Cancer Ther
|
2012
|
1.01
|
|
98
|
MicroRNA-related genetic variations as predictors for risk of second primary tumor and/or recurrence in patients with early-stage head and neck cancer.
|
Carcinogenesis
|
2010
|
1.01
|
|
99
|
Treatment with HIF-1alpha antagonist PX-478 inhibits progression and spread of orthotopic human small cell lung cancer and lung adenocarcinoma in mice.
|
J Thorac Oncol
|
2010
|
1.00
|
|
100
|
The cost of prostate cancer chemoprevention: a decision analysis model.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
1.00
|
|
101
|
Akt/mTOR counteract the antitumor activities of cixutumumab, an anti-insulin-like growth factor I receptor monoclonal antibody.
|
Mol Cancer Ther
|
2011
|
1.00
|
|
102
|
Cigarettes: a smoking gun in cancer chemoprevention.
|
J Natl Cancer Inst
|
2005
|
0.99
|
|
103
|
SELECT: the selenium and vitamin E cancer prevention trial.
|
Urol Oncol
|
2003
|
0.99
|
|
104
|
Repair capacity for UV light induced DNA damage associated with risk of nonmelanoma skin cancer and tumor progression.
|
Clin Cancer Res
|
2007
|
0.99
|
|
105
|
Pain and emotional well-being outcomes in Southwest Oncology Group-directed intergroup trial S0205: a phase III study comparing gemcitabine plus cetuximab versus gemcitabine as first-line therapy in patients with advanced pancreas cancer.
|
J Clin Oncol
|
2010
|
0.99
|
|
106
|
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study.
|
Cancer Causes Control
|
2011
|
0.98
|
|
107
|
Suppression of prostate tumor cell growth by stromal cell prostaglandin D synthase-derived products.
|
Cancer Res
|
2005
|
0.98
|
|
108
|
MicroRNA-related genetic variants associated with clinical outcomes in early-stage non-small cell lung cancer patients.
|
Cancer Res
|
2013
|
0.98
|
|
109
|
DeltaNp63 overexpression, alone and in combination with other biomarkers, predicts the development of oral cancer in patients with leukoplakia.
|
Clin Cancer Res
|
2009
|
0.97
|
|
110
|
Activation of protein kinase G up-regulates expression of 15-lipoxygenase-1 in human colon cancer cells.
|
Cancer Res
|
2005
|
0.97
|
|
111
|
American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.
|
Gynecol Oncol
|
2009
|
0.97
|
|
112
|
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group Study.
|
Clin Cancer Res
|
2006
|
0.97
|
|
113
|
Elevated levels of urinary prostaglandin e metabolite indicate a poor prognosis in ever smoker head and neck squamous cell carcinoma patients.
|
Cancer Prev Res (Phila)
|
2009
|
0.97
|
|
114
|
Increased 5-lipoxygenase expression and induction of apoptosis by its inhibitors in esophageal cancer: a potential target for prevention.
|
Carcinogenesis
|
2005
|
0.96
|
|
115
|
Feasibility of image-guided transthoracic core-needle biopsy in the BATTLE lung trial.
|
J Thorac Oncol
|
2013
|
0.96
|
|
116
|
The selenium and vitamin E cancer prevention trial.
|
World J Urol
|
2003
|
0.96
|
|
117
|
Antiangiogenic antitumor activities of IGFBP-3 are mediated by IGF-independent suppression of Erk1/2 activation and Egr-1-mediated transcriptional events.
|
Blood
|
2011
|
0.96
|
|
118
|
Genome-wide association study of genetic predictors of overall survival for non-small cell lung cancer in never smokers.
|
Cancer Res
|
2013
|
0.96
|
|
119
|
Comprehensive biomarker analysis and final efficacy results of sorafenib in the BATTLE trial.
|
Clin Cancer Res
|
2013
|
0.95
|
|
120
|
Design and progress of a trial of selenium to prevent prostate cancer among men with high-grade prostatic intraepithelial neoplasia.
|
Cancer Epidemiol Biomarkers Prev
|
2006
|
0.95
|
|
121
|
Does the level of prostate cancer risk affect cancer prevention with finasteride?
|
Urology
|
2008
|
0.95
|
|
122
|
Aspirin and colorectal cancer prevention in Lynch syndrome.
|
Lancet
|
2011
|
0.94
|
|
123
|
Combating resistance to anti-IGFR antibody by targeting the integrin β3-Src pathway.
|
J Natl Cancer Inst
|
2013
|
0.94
|
|
124
|
Prospective imaging assessment of mortality risk after head-and-neck radiotherapy.
|
Int J Radiat Oncol Biol Phys
|
2010
|
0.93
|
|
125
|
Epidermal growth factor receptor and K-Ras mutations and resistance of lung cancer to insulin-like growth factor 1 receptor tyrosine kinase inhibitors.
|
Cancer
|
2012
|
0.92
|
|
126
|
The methyltransferase inhibitor 5-aza-2-deoxycytidine induces apoptosis via induction of 15-lipoxygenase-1 in colorectal cancer cells.
|
Mol Cancer Ther
|
2005
|
0.92
|
|
127
|
In vitro sensitivity to ultraviolet B light and skin cancer risk: a case-control analysis.
|
J Natl Cancer Inst
|
2005
|
0.92
|
|
128
|
An intermittent approach for cancer chemoprevention.
|
Nat Rev Cancer
|
2011
|
0.92
|
|
129
|
Advances in the biology of lung cancer chemoprevention.
|
J Clin Oncol
|
2005
|
0.92
|
|
130
|
Phase III prostate cancer prevention trials: are the costs justified?
|
J Clin Oncol
|
2005
|
0.92
|
|
131
|
Differential peroxisome proliferator-activated receptor-gamma isoform expression and agonist effects in normal and malignant prostate cells.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
0.91
|
|
132
|
Inverse relationship between 15-lipoxygenase-2 and PPAR-gamma gene expression in normal epithelia compared with tumor epithelia.
|
Neoplasia
|
2005
|
0.91
|
|
133
|
The convergence of cancer prevention and therapy in early-phase clinical drug development.
|
Cancer Cell
|
2004
|
0.91
|
|
134
|
Genetic variations in the transforming growth factor-beta pathway as predictors of survival in advanced non-small cell lung cancer.
|
Carcinogenesis
|
2011
|
0.91
|
|
135
|
Combined targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways.
|
Clin Cancer Res
|
2005
|
0.91
|
|
136
|
Reduced 15S-lipoxygenase-2 expression in esophageal cancer specimens and cells and upregulation in vitro by the cyclooxygenase-2 inhibitor, NS398.
|
Neoplasia
|
2003
|
0.91
|
|
137
|
Induction of retinoic acid receptor-beta suppresses cyclooxygenase-2 expression in esophageal cancer cells.
|
Oncogene
|
2002
|
0.91
|
|
138
|
Systematic evaluation of apoptotic pathway gene polymorphisms and lung cancer risk.
|
Carcinogenesis
|
2012
|
0.90
|
|
139
|
RRIG1 mediates effects of retinoic acid receptor beta2 on tumor cell growth and gene expression through binding to and inhibition of RhoA.
|
Cancer Res
|
2006
|
0.89
|
|
140
|
Phase II clinical trial of N-(4-Hydroxyphenyl)retinamide and tamoxifen administration before definitive surgery for breast neoplasia.
|
Clin Cancer Res
|
2002
|
0.89
|
|
141
|
Changes in serum proteomic patterns by presurgical alpha-tocopherol and L-selenomethionine supplementation in prostate cancer.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.89
|
|
142
|
Intraarterial cisplatin with intravenous paclitaxel and ifosfamide as an organ-preservation approach in patients with paranasal sinus carcinoma.
|
Cancer
|
2003
|
0.89
|
|
143
|
MicroRNA profiling of salivary adenoid cystic carcinoma: association of miR-17-92 upregulation with poor outcome.
|
PLoS One
|
2013
|
0.88
|
|
144
|
Dominant negative signal transducer and activator of transcription 2 (STAT2) protein: stable expression blocks interferon alpha action in skin squamous cell carcinoma cells.
|
Mol Cancer Ther
|
2003
|
0.88
|
|
145
|
4-Nitroquinoline-1-oxide-induced mutagen sensitivity and risk of nonmelanoma skin cancer: a case-control analysis.
|
J Invest Dermatol
|
2006
|
0.88
|
|
146
|
Cyclin D1 and cancer development in laryngeal premalignancy patients.
|
Cancer Prev Res (Phila)
|
2009
|
0.87
|
|
147
|
Human epidermal receptor 2-amplified salivary duct carcinoma: regression with dual human epidermal receptor 2 inhibition and anti-vascular endothelial growth factor combination treatment.
|
Head Neck
|
2013
|
0.87
|
|
148
|
Repeat polymorphisms in estrogen metabolism genes and prostate cancer risk: results from the Prostate Cancer Prevention Trial.
|
Carcinogenesis
|
2011
|
0.87
|
|
149
|
15-Lipoxygenase-1 transcriptional silencing by DNA methyltransferase-1 independently of DNA methylation.
|
FASEB J
|
2008
|
0.87
|
|
150
|
Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions.
|
Eur J Cancer
|
2008
|
0.87
|
|
151
|
Identification and characterization of the human retinoid X receptor alpha gene promoter.
|
Gene
|
2006
|
0.87
|
|
152
|
Finasteride decreases the risk of prostatic intraepithelial neoplasia.
|
J Urol
|
2007
|
0.87
|
|
153
|
Unprecedented opportunities and promise for cancer prevention research.
|
Cancer Prev Res (Phila)
|
2010
|
0.86
|
|
154
|
Increased retinoic acid receptor-beta4 correlates in vivo with reduced retinoic acid receptor-beta2 in esophageal squamous cell carcinoma.
|
Cancer Epidemiol Biomarkers Prev
|
2005
|
0.85
|
|
155
|
Breast tissue accumulation of retinamides in a randomized short-term study of fenretinide.
|
Clin Cancer Res
|
2003
|
0.85
|
|
156
|
Chromosome instability in lymphocytes: a potential indicator of predisposition to oral premalignant lesions.
|
Cancer Res
|
2002
|
0.85
|
|
157
|
Suppression of type I interferon signaling proteins is an early event in squamous skin carcinogenesis.
|
Clin Cancer Res
|
2002
|
0.85
|
|
158
|
Genetic variations in regulator of G-protein signaling genes as susceptibility loci for second primary tumor/recurrence in head and neck squamous cell carcinoma.
|
Carcinogenesis
|
2010
|
0.85
|
|
159
|
Modulation of breast cancer risk by nonsteroidal anti-inflammatory drugs.
|
J Natl Cancer Inst
|
2008
|
0.84
|
|
160
|
Retracted
Molecular based treatment of oral cancer.
|
Oral Oncol
|
2003
|
0.84
|
|
161
|
Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict head and neck cancer patient second primary tumor/recurrence risk and response to retinoid chemoprevention.
|
Clin Cancer Res
|
2012
|
0.84
|
|
162
|
Telomere length and recurrence risk after curative resection in patients with early-stage non-small-cell lung cancer: a prospective cohort study.
|
J Thorac Oncol
|
2015
|
0.83
|
|
163
|
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions.
|
Cancer
|
2009
|
0.83
|
|
164
|
Nutritional prevention of cancer: new directions for an increasingly complex challenge.
|
J Natl Cancer Inst
|
2009
|
0.83
|
|
165
|
Budesonide versus placebo in high-risk population with screen-detected lung nodules: rationale, design and methodology.
|
Contemp Clin Trials
|
2010
|
0.83
|
|
166
|
Frontiers in cancer prevention research.
|
Cancer Res
|
2003
|
0.82
|
|
167
|
Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer.
|
Cancer
|
2010
|
0.82
|
|
168
|
Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride.
|
Cancer Epidemiol Biomarkers Prev
|
2012
|
0.82
|
|
169
|
Short telomere lengths in peripheral blood leukocytes are associated with an increased risk of oral premalignant lesion and oral squamous cell carcinoma.
|
Cancer
|
2013
|
0.82
|
|
170
|
Can selenium prevent colorectal cancer? A signpost from epidemiology.
|
J Natl Cancer Inst
|
2004
|
0.81
|
|
171
|
Cancer chemoprevention and cancer preventive vaccines--a call to action: leaders of diverse stakeholder groups present strategies for overcoming multiple barriers to meet an urgent need.
|
Cancer Res
|
2006
|
0.81
|
|
172
|
Identification of benzo(a)pyrene diol epoxide-binding DNA fragments using DNA immunoprecipitation technique.
|
Cancer Res
|
2003
|
0.81
|
|
173
|
Predictors of survival in never-smokers with non-small cell lung cancer: a large-scale, two-phase genetic study.
|
Clin Cancer Res
|
2012
|
0.81
|
|
174
|
Peroxisome proliferator-activated receptor-gamma suppresses cyclooxygenase-2 expression in human prostate cells.
|
Cancer Epidemiol Biomarkers Prev
|
2004
|
0.81
|
|
175
|
Detailed genome-wide SNP analysis of major salivary carcinomas localizes subtype-specific chromosome sites and oncogenes of potential clinical significance.
|
Am J Pathol
|
2013
|
0.80
|
|
176
|
Common genetic variants in cell cycle pathway are associated with survival in stage III-IV non-small-cell lung cancer.
|
Carcinogenesis
|
2011
|
0.79
|
|
177
|
Three-dimensional mRNA measurements reveal minimal regional heterogeneity in esophageal squamous cell carcinoma.
|
Am J Pathol
|
2012
|
0.79
|
|
178
|
Selenium, genetic variation, and prostate cancer risk: epidemiology reflects back on selenium and vitamin E cancer prevention trial.
|
J Clin Oncol
|
2009
|
0.79
|
|
179
|
Genetic variations in cell-cycle pathway and the risk of oral premalignant lesions.
|
Cancer
|
2008
|
0.79
|
|
180
|
Natural-agent mechanisms and early-phase clinical development.
|
Top Curr Chem
|
2013
|
0.78
|
|
181
|
Human telomerase reverse transcriptase mRNA is highly expressed in normal breast tissues and down-regulated in ductal carcinoma in situ.
|
Int J Oncol
|
2004
|
0.78
|
|
182
|
Phase I trial of weekly topotecan and gemcitabine in patients with solid tumors.
|
Am J Clin Oncol
|
2009
|
0.77
|
|
183
|
Phase II study of vinorelbine and docetaxel in the treatment of advanced non-small-cell lung cancer as frontline and second-line therapy.
|
Am J Clin Oncol
|
2010
|
0.77
|
|
184
|
Cancer prevention: strong science and real medicine.
|
J Clin Oncol
|
2005
|
0.77
|
|
185
|
RARbeta1': primed to fight retinoid resistance in lung carcinogenesis.
|
J Natl Cancer Inst
|
2005
|
0.77
|
|
186
|
Mortality in the randomized, controlled lung intergroup trial of isotretinoin.
|
Cancer Prev Res (Phila)
|
2010
|
0.76
|
|
187
|
COX-2 inhibitors and other NSAIDs in bladder and prostate cancer.
|
Prog Exp Tumor Res
|
2003
|
0.75
|
|
188
|
Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience.
|
Oncology
|
2009
|
0.75
|
|
189
|
Meeting Report: Fifth Annual AACR Frontiers in Cancer Prevention Research.
|
Cancer Res
|
2007
|
0.75
|
|
190
|
Letter from the Editor.
|
Cancer Prev Res (Phila)
|
2014
|
0.75
|
|
191
|
Looking forward to 2013--saluting the exceptional year in 2012.
|
Cancer Prev Res (Phila)
|
2013
|
0.75
|
|
192
|
John A. Milner: in memoriam (1947-2013).
|
Cancer Prev Res (Phila)
|
2014
|
0.75
|
|
193
|
Inaugural issue of Cancer Prevention Research.
|
Cancer Prev Res (Phila)
|
2008
|
0.75
|
|
194
|
Letter from the editor.
|
Cancer Prev Res (Phila)
|
2012
|
0.75
|
|
195
|
Cancer epidemiology, biomarkers & prevention and cancer prevention research: two journals, a common goal.
|
Cancer Prev Res (Phila)
|
2008
|
0.75
|
|
196
|
Cancer Prevention Research. Letter from the Editor.
|
Cancer Prev Res (Phila)
|
2009
|
0.75
|
|
197
|
Catalyzing Cancer Prevention Research CaPR: A New Year/New Opportunities.
|
Cancer Prev Res (Phila)
|
2016
|
0.75
|
|
198
|
Cancer epidemiology, biomarkers & prevention, and cancer prevention research: two journals, a common goal.
|
Cancer Epidemiol Biomarkers Prev
|
2008
|
0.75
|